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Abstract
Background: Vancomycin use is considered inappropriate in most hospitals. A particular concern
is the recent emergence of S. aureus with decreased susceptibility to vancomycin, making it
important to reduce overall exposure to vancomycin to minimize the incidence of VRE
(vancomycin-resistant enterococci). The aim of this work was to analyze the use of vancomycin and
the risk factors associated with inappropriate treatment.
Methods: A prospective survey was conducted on all patients receiving vancomycin between 1st
March 2002 and 30th September 2002 in a university-school hospital. Appropriateness of
vancomycin use was assessed, according to the criteria established by the Centers for Disease
Control and Prevention (CDC), at two time points: first, at the beginning of therapy, and second,
continuing after 72 hours.
Results: A total of 557 patients received vancomycin. Three hundred seventy-four (67.1%) were
under 60 years old, 374 (67.1%) had prolonged stays (>two weeks) in hospital, and 455 (81.7%)
were in the intensive care unit (ICU). Two hundred sixty-three patients (47.2%) had some invasive
device. In 324 (58.2%) patients the duration of vancomycin treatment was up to two weeks.
Vancomycin was inappropriately used in 65.7% during the first 24 hours and in 67% at the 72 hours
point according to CDC criteria [4]. The inappropriateness of vancomycin use during the first 24
hours was related to: patients aged less than 60 (OR 1.7; CI 95% 1.1–2.5), non-ICU patients (OR
1.5; CI 95% 1.0–2.4) and patients without neutropenia (OR 7.5; CI 95% 2.4–22.7). At 72 hours, the
inappropriateness of vancomycin use was related to: patients aged less than 60 (OR 1.5; CI 95%
1.0–2.3), non-ICU patients (OR 1.7; CI 95% 1.1–2.7) and patients without neutropenia (OR 8.0; CI
95% 2.6–24.3).
Conclusion: Vancomycin was abused. Patients aged less than 60, non-ICU patients and those who
did not present neutropenia were the principal groups at risk of inappropriate use.
Background
In recent decades, increases have been observed in antibi-
otic consumption and resistance to antimicrobials,
mainly in large hospitals [1]. More than half of all patients
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all prescribed antibiotics are inappropriate in respect of
drug choice, dose administered or duration of treatment
[2].
The development of vancomycin resistance illustrates the
alternation of success and failure that has characterized
the history of the antimicrobial age. This age started with
penicillin, the discovery of which was revolutionary.
Later, vancomycin proved active against all Gram-positive
cocci and for a time no resistance was found. It has
become one of the most frequently prescribed antibiotics
in hospitals, especially because of the increase of infec-
tions caused by methicillin-resistant Staphylococcus aureus
(MRSA) and Staphylococcus coagulase-negative [2]. Abuse
of this drug has favored the emergence of vancomycin-
resistant Enterococcus sp [3,4].
With the aim of reducing vancomycin resistance, the CDC
produced directives to orientate the use of this antibiotic.
Despite this initiative, several studies have shown that the
use of vancomycin remains high and, in about 34–67% of
cases, is considered inappropriate [1]. This inappropriate
usage may be due to the high level of resistance present in
hospitals where the MRSA and methicillin-resistant Sta-
phylococcus coagulase-negative are endemic[6].
The objective of this study was to evaluate the appropri-
ateness of vancomycin use, according to the rules of the
Hospital Infection Control Practices Advisory Committee
(HICPAC) [4], in a university-school hospital that has
high incidences of resistant Staphylococcus aureus and
methicillin-resistant Staphylococcus coagulase-negative
(46.4% and 42.2%, respectively). We also aimed to iden-
tify the risk factors associated with its inappropriate use.
Methods
Setting
The study was carried out in the Federal University of Sao
Paulo a teaching hospital between March and September
2002. It had previously been approved by the Ethics in
Research Committee. This 644-bed hospital performs kid-
ney, heart, bone marrow, liver and pancreas transplants.
As vancomycin is a restricted-use antibiotic in the hospi-
tal, prescription depended upon evaluation by the Anti-
microbial Rationalization Service. This department
evaluates all requests for restricted-use antimicrobials
according to completed requirement forms. When the
infectious disease specialist staff informed the assistant
physician about partial Gram-positive blood culture
results and, subsequently, the final results with complete
identification of the respective antibiogram, the data and
recommended antimicrobial therapy were discussed and
alterations could be suggested. One of the service infec-
tious disease specialists would make daily evaluations of
patients who had used vancomycin until discharge or
death, and would assess the indication for vancomycin
according to the HICPAC criteria [4].
The vancomycin prescription was prescribed by medical
residents in their respective specialty. They were oriented
by staff physicians, whose average years of qualification
were five years.
Table 1: Criteria for appropriate vancomycin use according to the CDC criteria [4]
Appropriate use
Serious infections caused by b-lactam-resistant Gram-positive microorganisms;
Infection caused by Gram-positive organisms in patients allergic to b-lactam antimicrobials;
Antibiotics treatment for colitis when there is a problem with metronidazole use or imminent life risk;
Surgical prophylaxis, with prosthesis implant, in institutions with high rates of oxacillin-resistant Gram-positive infections;
Neutropenics with extensive mucosite, infection related to venous catheters, previous prophylaxis with fluorquinolone, hypotension or sepsis.
Inappropriate use:
Routine surgical prophylaxis;
Febrile neutropenia that does not present isolation of oxacillin-resistant Gram-positive bacteria;
Treatment of a single blood culture for oxacillin-resistant Staphylococcus, coagulase-negative, if another culture collected simultaneously was 
sterile;
Empirical use, continuous, in patients whose cultures are negative for Gram-positive bacteria;
Presence of catheter and fever;
Decontamination of the gastrointestinal tract;
Prophylaxis for low birth weight infants;
Primary treatment of colitis by antibiotics;
Colonization by oxacillin-resistant Gram-positive bacteria;
Prophylaxis for patients in continuous peritoneal dialysis or hemodialysis;
Convenience treatment of infections by b-lactam-sensitive Gram-positive in hemodialysis patients;
Topical vancomycin use.Page 2 of 6
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To evaluate the appropriateness of vancomycin use, a pro-
spective cohort study was performed on patients who had
used the drug. Appropriateness was judged according to
the CDC criteria (Table 1) [4]. All patients who had been
treated more than once with vancomycin or who had
been treated for less than 24 hours were excluded from the
study.
The indication was assessed at the first 24 hours and after
72 hours, according to the CDC criteria [4]. These criteria
are described in Table 1, which relates to vancomycin
treatment of patients with (1) infections caused by β-
lactam-resistant Gram-positive microorganisms, (2) aller-
gies to this same class of antibiotics or (3) failure to
respond to metronidazole therapy for pseudomembra-
nous colitis.
The patients were evaluated according to their clinical and
demographic characteristics. The variables analyzed were:
sex, age, length of stay, ward, admission diagnosis, accord-
ing to ICD-9-CM (International Classification of Diseases,
nine revision, clinical modification), disease classification
according to McCabe-Jackson criteria [7], prior surgery,
presence of neutropenia, mechanical ventilation, presence
of a central venous catheter, and period and outcome of
vancomycin use.
Statistical Analysis
The obtained data from the completed forms were stored
in an ACCESS database, version 2.0, Microsoft C.O., Ire-
land. Univariate analysis of the risk factors was done by
Chi-square (X2) or Fisher's Exact Tests and continuous var-
iables were analyzed by Student's t test. A multiple logistic
regression model was used for multivariate analysis. P val-
ues lower than 0.05 were considered statistically signifi-
cant. The OR (odds ratio) and its respective confidence
interval estimates were 95%. Statistical analyses were per-
formed using SAS software version 8.0 (Statistical Analysis
System, Cary, NC, USA).
Results
During the study period, 667 treatments were evaluated.
Only patients who had used vancomycin a single time
were analyzed (557; 83.5%).
The average length of hospital stay was 39.8 days; the aver-
age length of hospital stay prior to vancomycin use was
15.1 days. The average total time of vancomycin use was
14.3 days, representing the majority of patients (324,
58.2%) in our analysis. The clinical and demographic
characteristics of the patients are listed in Table 2. Of the
patients studied, the average age was 49 years, 56.6% were
men, 47.2% were hospitalized in the ICU, Pediatrics and
Adult. Two hundred thirty six was submitted surgery
included gastrointestinal surgery in (194, 82.2%)
patients, genitourinary in (14, 6%) patients, neurological
surgery in (12, 5%) patients, orthopedic surgery in (8,
3.4%) patients and others surgery in (8, 3.4%) patients.
Central venous catheter was present in (354, 63.6%)
patients. Most (81.7%) patients had been hospitalized for
at least two weeks, and the principal reason for hospitali-
zation was infectious disease (22.6%). According to the
Table 2: Demographic data of the 557 Sao Paulo Hospital 
patients who used vancomycin between March 1st and September 
30th 2002
Variables N Percentage
Sex
Male 315 56.6
Female 242 43.4
Age
< 60 years 374 67.1
≥ 60 years 183 32.9
Length of hospital 
stay
< 2 weeks 102 18.3
≥ 2 weeks 455 81.7
Unit
ICU (Pediatrics and 
general)
263 47.2
General practice 158 28.4
Pediatrics 71 12.7
Surgery 47 8.4
Others 18 3.2
Diagnosis
Infectious diseases 126 22.6
Hematological diseases 66 11.8
Cardiac diseases 68 12.2
Malignancies disease 59 10.6
Neurological diseases 55 9.9
Gastrointestinal 
diseases
52 9.3
Gynecological-urinary 
diseases
43 7.7
Others 88 15.9
Neutropenia
Yes 28 5.0
No 529 95.0
Oral-Tracheal 
intubation
Yes 308 55.3
No 249 44.7
Central venous 
catheter
Yes 354 63.6
No 203 36.4
Vancomycin use 
period
< 2 weeks 324 58.2
≥ 2 two weeks 233 41.8
Outcome
Discharge 295 53.0
Death 262 47.0Page 3 of 6
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tially fatal diseases; by the criteria of Charlson, 87% of the
patients   had score under of 4  [8]. The general mortality
rate was 47%.
Vancomycin use was considered appropriate in 191 cases
(34.3%) during the first 24 hours and in 184 cases
(33.0%) after 72 hours. The principal indication for
appropriate use was the isolation of β-lactam-resistant
Gram-positive bacteria at both time points, as shown in
Table 3. Correspondingly, the rates of inappropriate use
were 65.7% and 67% at the 24-hour and the 72-hour,
respectively, as shown in Table 4. Half the inappropriate
vancomycin use (285 cases, 51.3%) at both time points
was because the patients were in critical clinical condi-
tions.
Univariate analysis showed that the risk factors associated
with inappropriate vancomycin use at the two time
points, according to the CDC criteria, were patients under
60 years old, those who were hospitalized in units other
than ICUs, and those without central venous catheters or
with a central venous catheter for no longer than two
weeks. In our analysis, patients who underwent surgery
did not have risk factors associated with misuse vancomy-
cin (Table 5). When the two time periods were examined
by multivariate analysis, inappropriate vancomycin use
was found to be in patients under 60 years old, without
neutropenia and outside ICUs (Table 6).
Discussion
The outbreak of Enterococcus spp resistance and highly
vancomycin-resistant Staphylococcus aureus in 2002 in the
USA limited the therapeutic options for treating Gram-
positive bacterial infections [9,10]. Even after the develop-
ment of strategies to hinder the dissemination of resist-
ance by formulating guidelines for rational use of
antimicrobials and, above all, appropriate vancomycin
use in clinical practice, quite the opposite has been
observed: bacterial resistance has been disseminated and
vancomycin use remains indiscriminate [11,12].
In our hospital, as in others [13], there were high inci-
dences of methicillin resistant Staphylococcus aureus, favor-
ing the empirical use and the abuse of vancomycin. Thus,
the factors most frequently associated with inappropriate
use of vancomycin were its empirical use without evi-
dence of infection. Other authors have obtained similar
results [5,14].
There was a high incidence of inappropriate vancomycin
use at both time points in our study, mainly in patients
who presented potentially fatal disease according to the
McCabe-Jackson criteria. Even, when Gram-positive bac-
terial infection was not identified at the 72 hour point,
therapy was not suspended and vancomycin administra-
tion was maintained because of the critical clinical condi-
tion of the patient. Take into account the high prevalence
of MRSA isolate at our hospital, were considered inappro-
priate use in critical ill patients, also, we were not liberal
in allowing its use in situation such as with presence cath-
eter and fever because was followed CDC guidelines that
is not considered adequate in these population. Although
Table 4: Analysis of the frequency of with which vancomycin use 
failed to meet appropriateness criteria in 557 patients in Sao 
Paulo Hospital between March 1st and September 30th 2002, 
according to the CDC criteria (HICPAC,1995), at the 24 hour 
and 72 hour time points
Criteria At the first 24 
hours
At the first 72 
hours
N % N %
Surgical prophylaxis 6 1.1 6 1.1
Suspect of hospital 
infection without cultures 
being obtained
7 1.3 7 1.3
Critical clinical condition 285 51.3 285 51.3
Presence of catheter and 
fever
38 6.8 38 6.8
Decontamination of the 
gastrointestinal tract
3 0.5 3 0.5
Eradication of MRSA 
colonization
2 0.3 1 0.2
Treatment (chosen for 
dosing convenience) for β-
lactam-sensitive Gram-
positive bacteria
25 4.5 33 5.8
Total 366 65.7 373 67.0
Table 3: Analysis of the frequency of with which vancomycin use 
met appropriateness criteria in Sao Paulo Hospital between 
March 1st and September 30th 2002, according to the CDC 
criteria (HICPAC,1995), at the 24 hour and 72 hour time points
Criteria 24 hours 72 hours
N % N %
Isolation of β-lactam-
resistant Gram-positive 
bacteria
165 29.6 159 28.5
Presence of extensive 
mucositis in neutropenic 
patients
1 0.2 1 0.2
Infection related to 
catheter in neutropenic 
patients
1 0.2 1 0.2
Hypotension and sepsis in 
neutropenic patients
24 4.3 23 4.1
Total 191 34.3 184 33.0Page 4 of 6
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mycin, there is no "gold standard" for determining the
appropriateness of use. They are not specific, particularly
with respect to MRSA endemic in the institution. Hamil-
ton et al also observed that vancomycin use was main-
tained empirically despite negative cultures [15].
On the other hand, Ena et al observed that vancomycin
was more frequently used in the ICU [2]. We found that
inappropriate use was more frequent in patients hospital-
ized in other non-critical units, mostly in younger
patients. These points negligence the use of vancomycin
in this population supposedly not at high risk.
We found that vancomycin use was appropriate for neu-
tropenic patients; there are certainly protocols for neutro-
penic patients that precisely indicate vancomycin since
1999, in our institution.
The external validity of the study was limited because this
is a highly complex tertiary hospital and therefore has a
higher incidence of antimicrobial resistance. Future stud-
ies must take small and medium sized hospitals or even
other areas of Brazil into consideration. However, it is
probably valid to extrapolate the main findings to most
Brazilian tertiary and teaching hospitals: difficulty in con-
trolling dissemination of resistance, expression of oxacil-
lin resistance and abuse of vancomycin.
It should also be considered that the CDC criteria were
not developed for hospitals with high levels of Gram-pos-
itive resistance. There is a need to develop protocols that
acknowledge the real situation in each institution [16,17].
The CDC has published criteria for prudent use, but they
are not specific, particularly with respect to institution
with high incidence of MRSA, particularly in unstable
condition even in the absence of evidence of a Gram-pos-
itive infection. Given that vancomycin use is inappropri-
ate in younger patients (under 60 years), without
Table 6: Multivariate analyses of risk factors for inappropriate vancomycin use, at the first 24 and 72 hours, according to the CDC 
criteria (HICPAC,1995), in 557 patients in Sao Paulo Hospital between March and September 2002
Variables Odds ratio IC (95%) p
CDC 24 hours
< 60 years 1.7 1.16 – 2.58 0.007
Unit (no UCI) 1.5 1.03 – 2.44 0.035
Without neutropenia 7.5 2.46 – 22.79 0.001
CDC 72 hours
<60 years 1.5 1.07 – 2.34 0.021
Unit (no UCI) 1.7 1.15 – 2.73 0.009
Without neutropenia 8.0 2.64 – 24.37 0.001
Table 5: Univariate analyses of risk factors for inappropriate vancomycin use, at the first 24 and 72 hours, according to the CDC 
criteria (HICPAC,1995), in 557 patients in Sao Paulo Hospital between March and September 2002
Variables Inapropriateness (24 h) p Inappropriateness (72 h) p
N(366) % N(373) %
Age
< 60 years 264 (70.5) 0.001 266 (71.3) 0.002
≥ 60 years 102 (56.3) 107 (58.5)
Unit
Others 210 (71.3) 0.001 215 (73.4) 0.001
UCI/UCI ped 156 (59.7) 158 (60.1)
Neutropenia
Yes 9 (32.1) 0.001 8 (32.1) 0.001
No 357 (67.6) 365 (68.9)
Central venous 
catheter
Yes 221 (62.7) 0.04 226 (64.1) 0.049
No 145 (71.3) 147 (72.3)
Central venous 
catheter
< 2 weeks 125 (69.9) 0.003 127 (69.5) 0.002
≥ 2 weeks 96 (56.7) 99 (57.9)Page 5 of 6
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neutropenia and venous catheterized for no longer than
two weeks, recommendations are necessary to minimize
usage in this population, since the CDC guidelines
emphasize the high risk population (patients with neutro-
penia, prolonged catheterization and hospitalized in
ICU). In view of this, it is important for future studies to
highlight this subpopulation in order to minimize inap-
propriate use.
Thus, our study has identified the factors in vancomycin
misuse and the places where use is inappropriate, making
possible a more direct intervention and the elaboration of
strategies to decrease this inappropriateness and that each
hospital should create institution-specific guidelines for
vancomycin use based on local microbial resistance pat-
terns.
Conclusion
Vancomycin was inappropriateness in patients aged less
than 60, non-ICU patients and those who did not present
neutropenia. It is necessary to elaborate in each hospital
specific guidelines for vancomycin use.
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